Opening book details…
Can I read A novel antibody-TCR (AbTCR) T-cell therapy is safe and effective against CD19-positive relapsed/refractory B-cell lymphoma on EtoBox?
A novel antibody-TCR (AbTCR) T-cell therapy is safe and effective against CD19-positive relapsed/refractory B-cell lymphoma by Pengcheng He; Haibo Liu; Bryan Zimdahl; Jie Wang; Minna Luo; Qi Chang; Fangzhou Tian; Fan Ni; Duo Yu; Huasheng Liu; Limei Chen; Huaiyu Wang; Mei Zhang; Stephan A. Grupp; Cheng Liu is a Medicine article available to read on EtoBox.
What is A novel antibody-TCR (AbTCR) T-cell therapy is safe and effective against CD19-positive relapsed/refractory B-cell lymphoma about?
## Purpose: A barrier to widespread adoption of chimeric antigen receptor (car) t-cell therapy is toxicity. to address this, we recently developed a novel antibody-t-cell receptor (abtcr) platform (trademarked as artemis) which was designed to leverage natural immune receptor signaling and regulation. the abtcr platform includes a gamma/delta (γδ) tcr-based abtcr construct and a separate co-stimulatory molecule, both engineered to be tumor-specific. here, we aim to assess the safety and preliminary efficacy of a cd19-directed abtcr t-cell therapy. ## Methods: We generated et019003 t cells, which are autologous cd19-directed abtcr t cells. we then conducted an early phase i study to evaluate the safety and preliminary efficacy of et019003 t cells for the treatment of cd19-positive relapsed/refractory (r/r) b-cell lymphoma. ## Results: Sixteen patients enrolled in this study and 12 patients were treated. of the 12 patients treated, 6 patients (50%) achieved a complete response (cr), and 4 (33%) achieved a partial response (pr) (best objective response rate [orr] of 83%). crs were durable, including 2 patients with ongoing crs for 22.7 months and 23.2 months. et019003 was well-tolerat
Who reads A novel antibody-TCR (AbTCR) T-cell therapy is safe and effective against CD19-positive relapsed/refractory B-cell lymphoma?
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Pengcheng He; Haibo Liu; Bryan Zimdahl; Jie Wang; Minna Luo; Qi Chang; Fangzhou Tian; Fan Ni; Duo Yu; Huasheng Liu; Limei Chen; Huaiyu Wang; Mei Zhang; Stephan A. Grupp; Cheng Liu
- Publisher
- Springer Science and Business Media LLC
- Published
- 2022
- Language
- EN
- Field
- Medicine (Health Sciences)